Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Lenzilumab (KB 003) is a humanized monoclonal antibody designed to target CSF2/GM-CSF, with applications in COVID-19 and studies on chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry |
Description | Lenzilumab (KB 003) is a humanized monoclonal antibody designed to target CSF2/GM-CSF, with applications in COVID-19 and studies on chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) [1] [2]. |
Molecular Weight | N/A |
CAS No. | 1229575-09-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Lenzilumab 1229575-09-0 inhibitor inhibit